Stock Price, News, Quote and Profile of HARROW INC(NASDAQ:HROW) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

HARROW INC

NASDAQ:HROW (4/26/2024, 7:00:02 PM)

After market: 10.53 0 (0%)

10.53

+0.53 (+5.3%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap372.34M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 217 full-time employees. The company went IPO on 2013-02-08. The firm is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. The company provides comprehensive portfolio of prescription and non-prescription pharmaceutical products. The firm offers pharmaceutical products for ophthalmic surgeries in the United States, as well as medications prescribed to treat patients managing chronic and acute eye conditions, such as dry eye disease, glaucoma, allergies, infections, and other ophthalmic inflammatory conditions. The company serves over 10,000 doctors, hospitals, and ambulatory service centers (ASCs) and regularly ship to over 1,500 institutional accounts each month.